



## **ROUND TABLE OF COMPANIES MEMBERSHIP**

Memorandum of Understanding

Feb 2022

### **Purpose of this document**

This Memorandum of Understanding, alongside the RDNZ Working with Pharma Industry policy 2019 document, outlines the conduct required of members to the Round Table of Companies.

### **RTC overview**

The Round Table of Companies meetings purpose is to create a forum to support a long-term relationship between Rare Disorders NZ (formerly NZORD) and those companies operating within the health sector with an interest in rare disease treatments, medical devices and services. The focus is on working towards recognition by the New Zealand government of the need for a Rare Disease National Framework and Policy which would include diagnosis, coordinated care, access to services, access to treatment, a national rare disease registry and research.

### **Code of conduct**

The RTC members adopt the Medicines New Zealand Code of Conduct<sup>1</sup> and each member of the round table of companies signs their agreement upon joining the Rare Disorders New Zealand Round Table of Companies. Special note is section 5 of the Medicines New Zealand Code of Conduct which indicates how companies should engage with Rare Disorders NZ as a patient advocacy group, and any patients who take part in these meetings also.

All parties further agree to conduct all activities and discussions in a fair and reasonable manner in compliance with all applicable competition laws, avoiding any potential or perceived negative impact upon competition. Any Member may abstain from any discussions or activities which it deems in its sole discretion are in conflict with this fair competition obligation.

### **Responsibilities**

Rare Disorders NZ will:

- Host two meetings a year for members in Wellington;
- Open the meeting with a presentation on the current medicines access situation in New Zealand;
- Coordinate membership and invoicing;
- Communicate regularly with members throughout the year.

---

<sup>1</sup>[https://www.medicinesnz.co.nz/fileadmin/user\\_upload/Code\\_of\\_Practice\\_Edition\\_17\\_published\\_April\\_2019\\_effective\\_September\\_2019.pdf](https://www.medicinesnz.co.nz/fileadmin/user_upload/Code_of_Practice_Edition_17_published_April_2019_effective_September_2019.pdf)



Member companies will:

- Offer expertise towards developing a proposed Rare Disorders National Framework and Action Plan for New Zealand;
- Share knowledge to enable RDNZ to improve the health and wellbeing of people living with rare disorders in New Zealand;
- Abide by the Code of Conduct and Policy documents referenced above.

### **Confidentiality**

Each member will consider all information disclosed by any other member as confidential.

Disclosure of uniquely commercially sensitive material and information during discussions of the Round Table of Companies by any member is strictly prohibited.

### **Duration**

The first term of RTC membership runs from 1 July 2019 to 30 June 2020.

### **Legal Effect**

The Parties acknowledge that the provisions set out in this MOU, other than those relating directly to confidentiality and compliance with applicable laws are not intended to be legally binding, nor does this MOU create any obligation to enter into a definitive commercial agreement.

Name: Lisa Foster  
Role: Chief Executive  
Company: Rare Disorders NZ  
Signature:  
Date:

Name:  
Role:  
Company:  
Signature:  
Date: